Compare IOSP & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOSP | NKTR |
|---|---|---|
| Founded | 1938 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 1998 | 1996 |
| Metric | IOSP | NKTR |
|---|---|---|
| Price | $85.22 | $70.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $93.00 | ★ $146.67 |
| AVG Volume (30 Days) | 125.4K | ★ 905.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | ★ 228.87 | N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $1,778,000,000.00 | $307,711,000.00 |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $6.10 | N/A |
| P/E Ratio | $69.48 | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $65.51 | $21.02 |
| 52 Week High | $92.14 | $109.00 |
| Indicator | IOSP | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 57.81 | 54.95 |
| Support Level | $79.30 | $64.30 |
| Resistance Level | $87.23 | $76.78 |
| Average True Range (ATR) | 1.88 | 3.48 |
| MACD | 0.18 | 0.11 |
| Stochastic Oscillator | 73.85 | 54.12 |
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Performance Chemicals segment that derives maximum revenue, provides technology-based solutions for its customers' processes or products in personal care, home care, agrochemical, construction, mining and other industrial markets. The Fuel Specialties segment develops, manufactures, blends, markets and supplies a range of specialty chemical products used as additives in diesel, jet, marine, fuel oil and other fuels. The Oilfield Services segment develops and markets chemical solutions for drilling, completion, production, DRA and oil and gas applications.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.